Self / alloimmune defense receptors for selective targeting of activated pathogenic T and NK cells
Engineering T cells with chimeric receptors to target activated pathogenic cells addresses unwanted immune activation in transplantation and cell transfer, enhancing therapeutic efficacy and reducing rejection and autoimmune risks.
Patent Information
- Application Number
- JP2020560284
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-04-26
- Filing Date
- 2019-04-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-04-25
AI Technical Summary
Current treatments for transplantation and adoptive cell transfer are hindered by unwanted activation of T cells and NK cells, leading to alloimmune responses and autoimmune conditions, which are often managed with immunosuppressive drugs that compromise the immune system and increase infection risk.
Engineering adoptive T cells to express chimeric receptors that selectively target activated pathogenic T and NK cells using auto/alloimmune defense receptors (ADRs) to prevent unwanted activation, allowing for the use of allogeneic cells without immune rejection.
The engineered T cells effectively eliminate activated pathogenic cells while sparing resting cells, enhancing therapeutic efficacy and reducing immune rejection, thereby improving transplantation success and preventing autoimmune disorders.
Smart Images

Figure 0007584127000001 
Figure 0007584127000002 
Figure 0007584127000003
Abstract
Description
[Technical field]
[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to U.S. Provisional Patent Application No. 62 / 662,817, filed April 26, 2018, which is incorporated by reference in its entirety herein.
[0002] [STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT] This invention was made with United States Government support under P50 CA126752 awarded by the National Institutes of Health and the National Cancer Institute. The United States Government has certain rights in the invention.
[0003] Embodiments of the present disclosure include at least the fields of immunology, cell biology, molecular biology and medicine. [Background technology]
[0004] In patients undergoing transplants or receiving therapeutic cells from a third party, unwanted activation of T cells and NK cells often promotes life-threatening alloimmune responses that lead to rejection of transplanted organs / tissues or the development of graft-versus-host disease (GvHD). Similarly, unwanted activation of autoreactive T cells can also lead to devastating autoimmune conditions such as diabetes mellitus, autoimmune colitis and multiple sclerosis. Currently, most of these diseases are not curable because pathogenic T cells cannot be selectively eliminated. Instead, patients are often treated with immunosuppressive drugs, which render the patient immunocompromised, making them more susceptible to infections and malignant transformation.
[0005] The present disclosure provides a solution to a long-standing need in the art for safe and effective tissue transplantation and adoptive cell transfer, including utilizing off-the-shelf cells, by enhancing the ability of the transferred cells to control pathogenic conditions due to unwanted activation of the immune system. Summary of the Invention
[0006] The present disclosure is directed to compositions and methods for cells used in adoptive transfer to control pathogenic conditions resulting from immune activation. The compositions and methods are applicable to autologous and allogeneic cells. Although some measures can be taken to reduce the reactivity of allogeneic cells in recipient individuals, these cells will still be targeted by the recipient's immune system (mainly T cells and NK cells) which recognizes them as foreign, resulting in rejection and limiting therapeutic benefits.
[0007] The present disclosure overcomes this challenge by modifying adoptive therapy cells to target activated pathogenic T, NK-T and NK cells to prevent or treat medical conditions associated with their presence. In certain embodiments, the present compositions and methods utilize adoptive T cell transfer using cells expressing receptors that selectively target pathogenic T cells while sparing resting T cells. In specific embodiments, the adoptive T cells for transfer are engineered to express chimeric molecules that target pathogenic T cells, expressing specific target molecules whose presence on T cells indicates pathogenic T cells. In certain embodiments, the present disclosure relates to auto / allo-immune defense receptors (ADRs) for selective targeting of pathogenic T cells.
[0008] Certain embodiments of the present disclosure include methods of protecting engineered allogeneic T cells from elimination in a host individual by providing the individual with cells equipped with an ADR. Embodiments also include methods of avoiding an allogeneic immune response in individuals undergoing, for example, tissue or organ transplantation.
[0009] In certain embodiments, the cells encompassed by the present disclosure have been or can be modified to enable them to survive in a recipient, including an allogeneic recipient. In specific cases, cells for adoptive cell therapy (including T cells, NKT cells, etc.) are suitable for use "off-the-shelf," referring to cells held in a repository, i.e., a bank, that can be provided (with or without further modification) to an individual who needs them for a specific purpose. In many cases, the individual is not the individual from whom the cells were originally derived. Cells used in this way may be pre-manufactured to express an ADR. However, in some cases, the cells are modified to express an ADR after they are obtained from the bank. Also, the cells deposited in the bank may or may not express a CAR or recombinant TCR, or the cells obtained from the bank may be subsequently modified to express a CAR or recombinant TCR. Such implementations facilitate the use of therapeutic cells from a third party without immune rejection by the host and without the need to manufacture a patient-specific product each time it is needed.
[0010] In certain embodiments, there is an isolated polynucleotide comprising a sequence encoding: (1) one or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or functional derivatives thereof, operably linked to (2) a signaling domain that promotes T cell activation. The polynucleotide may comprise an OX40-specific ligand, a 4-1BB-specific ligand, or a CD40L-specific ligand. The OX40-specific ligand may be OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof, or any other engineered protein that has specific binding ability to OX40. The 4-1BB-specific ligand may be 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof, or any other engineered protein that has specific binding ability to 4-1BB. The CD40L-specific ligand can be CD40, an antibody targeting CD40L, a CD40-Fc fusion, or any other engineered protein capable of specific binding to CD40L, or a combination thereof. In at least certain cases, the polynucleotide further comprises a sequence encoding a spacer, e.g., 10-220 amino acids in length, between (1) and (2). The spacer can have a sequence that facilitates surface detection by an antibody. For example, the spacer can be detectable by an anti-Fc Ab. The spacer can include an IgG Fc portion.
[0011] In certain embodiments, the polynucleotide of the present disclosure may further encode a chimeric antigen receptor, a T cell receptor, or both. The polynucleotide may be in any form, including present on a vector, such as a viral vector (retroviral vector, lentiviral vector, adenoviral vector, or adeno-associated viral vector) or a non-viral vector (plasmid, transposon, etc.). In certain cases, the polynucleotide is present in a cell, including a eukaryotic cell or a bacterial cell. The cell may be an immune cell, such as a T cell. The cell may be engineered. The cell may include one or more chimeric antigen receptors (CARs) and / or one or more engineered T cell receptors (TCRs).
[0012] The polypeptide expressed by any polynucleotide encompassed in the present disclosure is included as part of the present disclosure.Specific embodiments include a polypeptide that comprises: (1) one or more of OX40 specific ligand, 4-1BB specific ligand, and CD40, (2) operatively linked to a signaling domain that promotes T cell activation.The signaling domain that promotes T cell activation can be derived from CD3 zeta subunit, DAP12, Fc receptor, or a combination thereof.
[0013] Any cell encompassed by this disclosure is part of this disclosure. In a specific embodiment, any chimeric receptor expressing cell is part of this disclosure, including cells comprising any polynucleotide and / or any polypeptide as contemplated herein. The cell may be an engineered cell. The cell may be an immune cell, such as a T cell, including a CAR-transduced T cell and / or a T cell receptor (TCR)-transduced T cell. In a specific embodiment, the cell is engineered to lack endogenous expression of one or more genes, for example, to lack one or more of 4-1BB, OX40 and / or CD40L. The cell may be engineered using CRISPR / Cas9, zinc finger nucleases, TALE nucleases, or meganucleases. Alternatively, the cell may be engineered to prevent surface expression of the ADR ligand, for example, by capturing the ADR ligand with a specific antibody or receptor anchored to the endoplasmic reticulum or other intracellular compartment.
[0014] In one embodiment, there is a method of avoiding rejection of allogeneic cells, tissues, or organs in an individual, comprising delivering to the individual an effective amount of allogeneic immune cells that contain an extracellular domain that targets a compound selectively present on activated T cells and express an engineered chimeric receptor that includes CD3 zeta, said delivering resulting in said individual: (1) inhibition of endogenous alloreactive T cells in the individual, and / or (2) suppression of NK cell activation in the individual. In a specific embodiment, the allogeneic cells are allogeneic immune cells that express a chimeric receptor. The allogeneic cells may express a chimeric antigen receptor and / or an engineered T cell receptor. The allogeneic immune cells may be delivered to the individual before, during, and / or after tissue and / or organ transplantation in the individual. In a specific case, the activated T cells are pathogenic T cells.
[0015] In one embodiment, there is a method of selectively targeting activated T cells in an individual, comprising providing to the individual an effective amount of cells expressing an engineered chimeric receptor, the chimeric receptor comprising: (1) an extracellular domain that targets a compound selectively present on activated T cells, and (2) a signaling domain that promotes T cell activation. The signaling domain that promotes T cell activation can be derived from CD3 zeta subunit, DAP12, Fc receptor, any ITAM-containing sequence, or a combination thereof. In a specific instance, the activated T cells are pathogenic T cells.
[0016] In certain embodiments, there is a method of preventing or treating a medical condition associated with activated T cells in an individual, comprising delivering to the individual an effective amount of an immune cell expressing an engineered chimeric receptor that selectively targets the activated T cells, the chimeric receptor comprising: (1) an extracellular domain that targets a compound selectively present on activated T cells, and (2) a signaling domain that promotes T cell activation. The medical condition can be an autoimmune disorder, such as, for example, graft rejection, graft versus host disease, type I diabetes, multiple sclerosis, autoimmune colitis, or a combination thereof.
[0017] In one embodiment, there is a method of avoiding NK cell-mediated host rejection of allogeneic T cells, allogeneic tissues, or allogeneic organs in an individual, comprising providing to the individual an effective amount of immune cells expressing an engineered chimeric receptor that includes an extracellular domain that targets a compound selectively present on activated T cells and also includes a signaling domain that promotes T cell activation. The immune cells expressing the engineered chimeric receptor are, in certain cases, allogeneic T cells. The immune cells may express a chimeric antigen receptor and / or an engineered T cell receptor. The amount of immune cells expressing the engineered chimeric receptor provided to the individual is about 1 ml. 2 10 per 2 ~10 12The number of cells expressing the chimeric receptor may range from 1 to 100. The cells expressing the chimeric receptor may be provided to the individual systemically or locally. The immune cells may be T cells. The immune cells may be delivered to the individual once, or more than once.
[0018] The foregoing has outlined rather broadly the features and technical advantages of the present disclosure so that the detailed description that follows may be better understood. Below are set forth additional features and advantages that form the subject matter of the claims. Those skilled in the art should appreciate that the concepts and specific embodiments disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the designs. Those skilled in the art should also appreciate that such equivalent constructions do not depart from the spirit and scope as set forth in the appended claims. The novel features believed to be inherent to the designs disclosed herein, both in terms of their construction and method of operation, together with further objects and advantages, will be better understood when the following description is considered in conjunction with the accompanying drawings. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only, and is not intended to define the scope of the present disclosure. [Brief description of the drawings]
[0019] For a more complete understanding of the present disclosure, the following description should be read in conjunction with the accompanying drawings.
[0020] [Figure 1A-E]ADRs can be expressed on the cell surface of immune cells to enhance cytotoxicity against their respective targets. (Figure 1A) Schematic of ADR. GFP is optional. (Figure 1B) Expression of ADR on the cell surface. (Figure 1C) Proliferation of ADR T cells after transduction. (Figure 1D) Cytotoxicity of ADR T cells against target cells expressing the ADR ligand. (Figure 1E) Proliferation of wild-type and 4-1BB KO T cells expressing 4-1BB ADR and their cytotoxicity against 4-1BB+ targets. This shows that proliferation and cytotoxicity can be further enhanced by knocking out the ADR ligand on T cells, demonstrating that co-expression of ADR and its ligand in T cells is not required for ADR- T cell proliferation or function.
[0021] [Figure 2A-E] Selective expression of ADR ligands on activated T cells allows for their selective elimination by ADR T cells. (Figure 2A-C) Expression of ADR ligands on resting versus activated T cells after TCR stimulation. (Figure 2D) Lack of cytotoxicity of ADR T cells against resting CD4+ and CD8+ T cells. (Figure 2E) Elimination of activated CD4+ and CD8+ T cells by ADR T cells after 48 h of co-culture.
[0022] [Figure 3A-F] Expression of 4-1BB ADR protects T cells from immune rejection in the MLR model. (Figure 3A) Representative dot plots showing that TCRKO T cells co-expressing ADR are protected from rejection after co-culture with allogeneic PBMCs at an ADR T:PBMC ratio of 1:10. (Figure 3B-C) Absolute numbers of donor and allogeneic T cells in co-culture. (Figure 3D-F) Same for virus-specific ADR T cells.
[0023] [Figure 4A-C]In in vitro mixed lymphocyte reactions, expression of ADR protects virus-specific allogeneic T cells from immune rejection. (Figure 4A) Representative dot plots showing that ADR VSTs are protected from immune rejection by recipient allogeneic PBMCs. (Figure 4B-C) Absolute numbers of recipient T cells and donor VSTs at various time points during the MLR.
[0024] [Diagram 5] ADR VST retains antiviral function. ADR VST was co-cultured with monocytes pulsed with a viral pepmix. Monocyte counts showed that ADR VST eliminated virus-infected cells as well as unmodified VST.
[0025] [Figure 6A-H] Activated NK cells upregulate ADR ligands and can be selectively targeted by ADR T cells. (Figure 6A-B) 4-1BB expression on resting versus activated NK cells. (Figure 6C) Residual numbers of resting versus activated NK cells after 24 h of co-culture with 4-1BB ADR T cells. (Figure 6D) MHC-depleted ADR T cells protect against immune rejection by allogeneic PBMCs by controlling NK cell proliferation. (Figure 6E) Absolute numbers of donor T cells and allogeneic NK cells in co-culture. (Figure 6F) Upon 48 h of co-culture at a 1:1 E:T ratio, MHC-depleted ADR T cells resist immune rejection by NK cells. (Figure 6G-H) ADR T cells control proliferation of alloreactive NK cells during MLR with PBMCs. (Figure 6H) Absolute numbers of NK cells are plotted.
[0026] [Figure 7A-E]ADR expression protects allogeneic T cells from immune rejection in vivo. (FIG. 7A) Schematic of a mouse model of immune rejection in which T cells from HLA-A2+ donors were given to mice after sublethal irradiation, followed by allogeneic HLA-A2- T cells 4 days later. (FIG. 7B-C) Control T cells from HLA-A2- donors were rejected by day 18, whereas ADR-expressing cells were protected. (FIG. 7C) Absolute numbers of T cells from HLA-A2+ and HLA-A2- donors at various time points. (FIG. 7D) Modified in vivo model in which mice were given whole PBMCs (containing both T and NK cells) from donor 1 instead of allogeneic T cells. (FIG. 7E) Representative flow plots showing that ADR T cells protected mice from immune rejection and from the rapid development of lethal GvHD.
[0027] [Figure 8A-E] Co-expression of CAR and ADR maintains the function of both receptors. (Figure 8A) Schematic of immune cells co-expressing ADR and CAR. (Figure 8B) Co-expression of CAR and ADR on the cell surface. (Figure 8C) Cytotoxicity of CAR-ADR T cells against NALM-6 (CD19+ CAR target). (Figure 8D) Cytotoxicity of CAR-ADR T cells against activated T cells (ADR target). (Figure 8E) Cytotoxic activity of CAR-ADR T cells against both targets when simultaneously co-cultured with both cell targets.
[0028] [Figure 9A-E] CAR-ADR T cells are protected from immune rejection and exert potent antitumor activity. (Figure 9A) Schematic of mouse model. Mice were given allogeneic T cells from donor 1 and b2mKO NALM6 24 hours apart, followed by a single dose of CAR-ADR T cells from donor 2. (Figure 9B) Dynamics of T cells from donor 2 in peripheral blood. (Figure 9C) Dynamics of T cells from donor 1 in the experimental group. (Figure 9D) Leukemia burden in mice. (Figure 9E) Overall survival of mice.
[0029] [Figure 10A-C]In solid tumor models, CAR-ADR T cells are protected from immune rejection and exert potent antitumor activity. (Figure 10A) Schematic of mouse model. Mice were given allogeneic T cells from donor 1 and b2mKO neuroblastoma cell line CHLA255 24 hours apart, followed by a single dose of CAR-ADR T cells from donor 2. (Figure 10B) GD2 CAR T cells from donor 2 were rejected by D18, whereas CAR-ADR T cells resisted allogeneic rejection and persisted in peripheral blood. (Figure 10C) Tumor burden in mice. * indicates xenogeneic GvHD-related death in the ATC+GD2 CAR T group.
[0030] [Figure 11A-E] TCR knockout CAR-ADR T cells are protected from immune rejection and exert potent anti-tumor activity. (Figure 11A) Schematic of mouse model. Mice received allogeneic T cells from donor 1 and b2mKO NALM6 24 hours apart, followed by a single dose of TCR-edited CAR-ADR T cells from donor 2. (Figure 11B) Dynamics of T cells from donor 2 in peripheral blood. (Figure 11C) Dynamics of donor 1 T cells in the experimental group. (Figure 11D) Leukemia burden in mice. (Figure 11E) Overall survival of mice.
[0031] [Figure 12A-D] ADR T cells protect mice from lethal xenogeneic GvHD. (Figure 12A) Schematic of the model. (Figure 12B) Expansion of FFluc-labeled ADR T cells in vivo. (Figure 12C) Kinetics of weight gain and loss in mice. (Figure 12D) Overall survival rate of mice.
[0032] [Figure 13A-G]Second generation ADR (ADR.28 zeta) with CD28 intracellular signaling domain. (Figure 13A) Structure of ADR.28 zeta. (Figures 13B-C) In vitro cytotoxicity of ADR.28 zeta against target expressing cell lines. (Figures 13D-G) ADR.28 zeta protected mice from xenogeneic GvHD. (Figure 13D) Schematic of the model. (Figure 13E) In vivo proliferation of FFLuc-labeled ADR.28 zeta T cells. (Figure 13F) Kinetics of mouse weight gain and loss. (Figure 13G) Overall survival of mice.
[0033] [Figure 14] Cytotoxicity of ADR-expressing cells in cancer. (Left) Cytotoxicity of 4-1BB ADR-expressing T cells against HDLM-2 Hodgkin lymphoma cells. (Right) Cytotoxicity of 4-1BB ADR-expressing T cells against K562 chronic myeloid leukemia (CML) cells. Absolute tumor cell counts are shown after 48 hours of co-culture at a 1:1 effector-to-target ratio. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] As used herein, the words "a" and "an" when used in conjunction with the word comprising, refer to "one or more," including the claims. Some embodiments of the present invention consist of, or consist essentially of, one or more elements, method steps, and / or methods of the present invention. It is contemplated that any method and composition described herein can be implemented with respect to any other method or composition described herein.
[0035] Throughout this specification, unless the context requires otherwise, the words "comprise", "comprises" and "comprising" will be understood to imply the inclusion of the stated step or element or group of steps or elements, but not the exclusion of any other step or element or group of steps or elements. "Consisting of" means including and limited to what follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the recited elements are necessary or mandatory, and that no other elements may be present. "Consisting essentially of" means including any elements recited after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in this disclosure for the recited elements. Thus, the phrase "consisting essentially of" indicates that the recited elements are necessary or mandatory, but that other elements are not optional and may or may not be present depending on whether they affect the activity or action of the recited elements.
[0036] Throughout this specification, reference to "one embodiment," "an embodiment," "a particular embodiment," "a related embodiment," "a particular embodiment," "an additional embodiment," or "a further embodiment," or combinations thereof, means that the particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, the appearances of such phrases in various places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0037] The term "subject" as used herein generally refers to an individual in need of treatment for any kind of medical condition. The subject can be any kind of animal. The subject can be any biological or animal subject that is the object of a method or substance, including mammals, such as humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), household pets (e.g., dogs, cats, and rodents), horses, and transgenic non-human animals. The subject can be, for example, a patient who has or is suspected of having a disease (which may be referred to as a medical condition), such as one or more infectious diseases, one or more genetic disorders, one or more cancers, or any combination thereof. The disease can be pathogenic. The subject may be or have been treated with antibiotics. The subject may be asymptomatic. The subject may be a healthy individual. The term "individual" can also be used interchangeably, at least in some cases. As used herein, a "subject" or "individual" may or may not be housed in a medical facility, and may be treated as an outpatient in a medical facility. An individual may receive one or more pharmaceutical compositions via the internet. An individual may include a human or non-human animal of any age, and thus includes adults and juveniles (i.e., children) and infants, including individuals in utero. An individual may be of any breed and sex. As the term is not intended to imply a need for medical treatment, an individual may be voluntarily or involuntarily part of an experiment, whether in the service of a clinical trial or basic science research.
[0038] The term "engineered" as used herein refers to a molecule that does not occur in nature and that has been produced artificially, for example by recombinant genetic techniques standard in the art.
[0039] In the context of this disclosure, an "effective amount" or a "therapeutically effective amount" refers to an amount of cells that, when administered to an individual, allows for targeting of activated T cells and / or alleviates the signs and / or symptoms of a medical condition or prevents a medical condition. The actual amount administered can be determined based on tests performed either in vitro or in vivo where the functional immune cells exhibit pharmacological activity against the medical condition.
[0040] I. Self / Alloimmune Defense Receptors and Compositions and Uses Thereof The present disclosure encompasses synthetic chimeric receptor molecules that provide selective targeting of activated T cells, including pathogenic T cells. These engineered molecules are synthetic molecules and can be produced by recombinant techniques. These molecules can be referred to as self / alloimmune defense receptors that target activated T cells, including activated pathogenic T cells, with high specificity, for example.
[0041] In certain embodiments, the self / alloimmune defense receptor (ADR) comprises an entity that targets one or more compounds that are upregulated on activated T cells. The compounds that are upregulated on activated T cells can be any one or combination, but in specific embodiments, OX40, 4-1BB and CD40L are upregulated on activated T cells, which are the targets that the ADR targets. In certain embodiments, the ADR is present on allogeneic immune cells that are allogenic with respect to the individual that receives the cells. In another example, the ADR is expressed on autologous T cells, xenogeneic cells, and / or synthetic cells.
[0042] (A. Autologous / Allologous Immune Defense Receptor (ADR) Molecules) ADR molecules are synthetic, non-naturally occurring molecules, artificially produced, that contain at least (1) an extracellular domain that targets a compound selectively present on activated T cells (in specific embodiments, the extracellular domain is a protein or functional fragment or derivative thereof that targets one or more compounds that are upregulated on activated T cells), and (2) a signaling domain that promotes T cell activation, such as those derived from CD3 zeta subunit, DAP12, and Fc receptor, or other ITAM-containing sequences. ADR molecules can comprise, consist of, or consist essentially of elements (1) and (2). In at least certain cases, ADRs contain one or more components of a type I transmembrane protein and / or one or more components of a type II transmembrane protein.
[0043] In a specific embodiment, the ADR molecule comprises an extracellular domain that selectively binds to an associated protein on activated T cells. For example, the ADR extracellular domain may comprise a ligand for a receptor on activated T cells, or the ADR extracellular domain may comprise a receptor for a ligand on activated T cells.
[0044] In a specific embodiment, in the ADR molecule, the extracellular domain comprises a ligand for OX40, a ligand for 4-1BB, and / or CD40. In these particular examples, the relevant proteins on activated T cells are OX40, 4-1BB, and CD40L, respectively. In alternative embodiments, other specific compositions on activated T cells are targeted. For example, other activation markers that are upregulated on the cell surface of T cells (e.g., CD69, CD25, CD71, etc.) can be targeted using a similar approach. In such cases, the corresponding ADR molecule will have a targeting moiety that is derived from a CD69 ligand, a CD25 ligand, or a CD71 ligand, or an antibody, respectively, rather than a 4-1BB / OX40 specific ligand.
[0045] In some cases, in contrast to non-activated T cells, activated T cells with upregulated OX40 expression are targeted. To target these activated T cells, ADRs may utilize a ligand for OX40 so that activated T cells can be targeted. In the case where a ligand for OX40 is utilized in ADRs, the ligand for OX40 may be any suitable ligand for OX40, such as at least OX40L, an antibody (or functional fragment thereof) that binds to OX40, a fusion of Fc and OX40L, or functional derivatives or fragments thereof. OX40L is also called tumor necrosis factor (ligand) superfamily member 4 (tax-transcriptionally activated glycoprotein 1, 34 kDa), OX40L, CD252, TNFSF4, TXGP1, OX-40L, or gp34.
[0046] In some cases, in contrast to non-activated T cells, activated T cells in which expression of 4-1BB is upregulated are targeted. To target these activated T cells, the ADR may utilize a ligand of 4-1BB so that it can target activated T cells. In the case where a ligand for 4-1BB is utilized in the ADR, the ligand for 4-1BB may be any suitable ligand for 4-1BB, such as 4-1BBL, an antibody (or a functional fragment thereof) that targets 4-1BB, a fusion of Fc and 4-1BBL, or a functional derivative or fragment thereof.
[0047] In certain cases, in contrast to non-activated T cells, activated T cells with upregulated expression of CD40L are targeted. To target these activated T cells, ADRs may utilize a receptor for CD40L so that they can target activated T cells. In the case where a receptor for CD40L is utilized in ADRs, ADRs may include CD40 (which may also be referred to as Bp50, CDW40, TNFRSF5, or p50), an antibody (or functional fragment thereof) that targets CD40L, or functional derivatives or fragments thereof.
[0048] In some cases, the ADR molecule contains two or more extracellular domains to facilitate targeting of activated T cells. Such combinations may enhance targeting of activated T cells in general or allow specific targeting of a particular subset of activated T cells. For example, the ADR may contain both OX40L and 4-1BBL as extracellular domains in the same ADR molecule to allow targeting of activated T cells that express either OX40 or 4-1BB. An example of such a combination would selectively target activated T cells that express either OX40 or 4-1BB, regardless of whether those activated T cells also express CD40L. Similarly, the ADR may contain both CD40 and OX40L to target activated T cells that express either CD40L or OX40, regardless of whether those activated T cells also express 4-1BB.
[0049] In the ADR molecule, the extracellular domain may be operatively linked to one or more components, including components that are part of the ADR molecule. One such component may be a protein that mediates downstream signaling during T cell activation. In a particular embodiment, the ADR comprises CD3 zeta (also called CD247, CD3-zeta, CD3H, CD3Q, CD3Z, IMD25, T3Z, or TCRZ) or a functional fragment or derivative thereof. CD3 zeta mediates downstream ITAM-derived signaling during T cell activation. Other ITAM-containing signaling domains may be from DAP12, Fc receptors, other CD3 subunits, and the like. The signaling domain may be non-covalently linked to the ADR via another domain.
[0050] In certain embodiments, the ADR comprises a spacer between CD3 zeta and the extracellular protein targeting one or more compounds upregulated on activated T cells. In other cases, no spacer is utilized. The spacer may comprise a sequence that is inactive or contributes substantially little or nothing to any function that the ADR may have. Meanwhile, in other cases, the spacer comprises a sequence that, for example, enhances the function of the ADR and / or allows the ADR to be detectable and / or targeted for inhibition. In specific embodiments, the spacer comprises an encoded protein sequence that facilitates detection of cells expressing the ADR. For example, the spacer may encode an Fc region or a fragment thereof that would allow for surface detection of cells using, for example, an anti-Fc Ab. In certain embodiments, the spacer provides separation between the ligand binding domain and the membrane, for example to avoid potential steric hindrance caused by the linkage of a type II transmembrane protein (4-1BBL, OX40L) with a type I ADR backbone (TM, signaling domain). The spacer may have any suitable length, for example, about 10 to 220 amino acids. The length of the spacer can be in the range of 10-220, 10-200, 10-150, 10-100, 10-50, 25-200, 25-150, 25-100, 25-75, 25-50, 50-200, 50-150, 50-125, 50-100, 50-75, 75-200, 75-150, 75-100, 100-200, 100-175, 100-150, 100-125, 125-200, 125-175, 125-150, 150-200, 150-175, 175-200, etc. The spacer can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210 or 220 amino acids in length. In other cases, the spacer is less than 10 amino acids or more than 200 amino acids.
[0051] In some cases, the ADR comprises one, two, three or more costimulatory domains that enhance cytokine production from cells expressing the ADR. The costimulatory domains may be derived from the intracellular signaling domains of costimulatory proteins, such as, for example, CD28, CD27, 4-1BB, OX40, ICOS, CD30, HVEM, CD40, etc. By way of example only, when the ADR comprises 4-1BBL, the costimulatory domain of the ADR may or may not be from 4-1BB.
[0052] In some embodiments, the ADR will include a transmembrane domain, which may be of any kind, so long as it allows the CD3 zeta component of the ADR to be located intracellularly and the extracellular domain that targets one or more compounds upregulated on activated T cells to be located extracellularly. In another example, the ADR is a soluble protein (e.g., ADR-CD3 T cell engager protein) that can bind to the respective ligand on activated T cells and promote cytotoxicity by crosslinking the TCR. If the extracellular domain is from a surface protein with a transmembrane domain (e.g., CD40), the ADR may include a transmembrane domain from the corresponding endogenous molecule. In some cases where the ADR molecule includes one or more costimulatory domains, the transmembrane domain (TM) may be from the same endogenous molecule with the costimulatory domain. Examples of TM include those from CD3, CD8α, CD27, CD28, 4-1BB, OX40, CD4, etc.
[0053] In one example of an ADR polypeptide, the components may be in a particular order from the N-terminus (N) to the C-terminus (C). In the case of a generic ADR, the receptor may comprise one of the following (by way of example only), where the extracellular domain comprises a protein that selectively binds to an associated protein on activated T cells: N-extracellular domain-signaling domain-C N-extracellular domain-CD3 zeta-C N-extracellular domain-spacer-CD3zeta-C N-extracellular domain-spacer-costimulatory domain-CD3 zeta-C N-extracellular domain-spacer-two costimulatory domains-CD3zeta-C N-two extracellular domains-spacer-costimulatory domain-CD3 zeta-C N-2 extracellular domains-spacer-2 costimulatory domains-CD3 zeta-C
[0054] In any case, the transmembrane domain may be C-terminal to the spacer. A signal peptide may be utilized at the N-terminus to drive expression of type II ligands (e.g., OX40L and 4-1BBL) on type I transmembrane protein backbones (e.g., transmembrane domains, signaling domains, CD3 zeta).
[0055] In some cases, the ADR comprises one or more detectable markers, such as colorimetric, fluorescent and / or radioactive markers, including green fluorescent protein, blue fluorescent protein, and the like.
[0056] Although ADR may be produced synthetically as a protein, ADR may be in the form of a polynucleotide or a polypeptide expressed by a polynucleotide. Recombinant techniques for producing ADR polynucleotides and ADR polypeptides are known in the art.
[0057] In certain cases, ADR polynucleotide is part of an expression construct that is in an expression construct or on a vector, and the vector can be a viral vector or a non-viral vector.An example of a non-viral vector is a plasmid.An example of a viral vector is a lentiviral vector, a retroviral vector, an adenoviral vector, and an adeno-associated viral vector.Any vector that expresses ADR will have suitable elements to allow expression in eukaryotic cells, including immune cells such as T cells, NK cells, or NKT cells.These suitable elements include promoters and the like.
[0058] 4-1BB ADR (SEQ ID NO: 1) MEFGLSWLFLVAILKGVQCGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVAKAGVYYVFFQLELRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVT PEIPAGLPSPRESEESKYGPPCPPCGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGKKDPKFWVLVVVGGVLACYSLLVTVAFIIFWVRSRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSAAAGGGGSGGGGSGGGGSMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEDATYGKLTLKFICTTGKLPVPWPT LVTTFTYGVQCFARYPDMHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0059] OX40 ADR MEFGLSWLFLVAILKGVQCQVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVLESKYGPPCPPPCPGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGKKDPKFWVLVVVGGVLACYSLLVTVAFIIFWVRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGGKGHDGLYQGLSTATKDTYDALHMQALPPRTSAAAGGGSGGGSGGGSGMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICCTTGKLPVPWPTLVTTFTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIEDGSVQLADHYQQNTPIGDGGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0060] CD40L ADR MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRESKYGPPCPPCPGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKKDPKFWVLVVVGGVLACYSLLVTVAFIIFWVRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRTSAAAGGGGSGGGGSGGGGSMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
[0061] In certain embodiments, the extracellular domain that targets activated T cells comprises an antibody or a functional fragment or derivative thereof.As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to an antigen.Antibody can be an intact immunoglobulin from natural or recombinant sources, or it can be an immunoreactive part of an intact immunoglobulin.Antibody is typically a tetramer of immunoglobulin molecules. The antibodies of the present invention may exist in a variety of forms, such as polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)2, as well as single chain antibodies and humanized antibodies (Harlow et al., 1999, "Using Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, "Antibodies: A Laboratory Manual", Cold Spring Harbor, NY; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).
[0062] In some cases, the extracellular domain of the ADR comprises an antibody fragment. The term "antibody fragment" refers to a portion of an intact antibody and refers to the antigen-determining variable region of the intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, linear antibodies, scFv antibodies, and multispecific antibodies formed from antibody fragments.
[0063] Synthetic antibodies may be used in ADRs. The term "synthetic antibody" as used herein refers to an antibody produced using recombinant DNA technology, such as an antibody expressed by a bacteriophage as described herein. The term should also be construed to mean an antibody produced by synthesis of a DNA molecule encoding the antibody, which DNA molecule expresses an antibody protein or an amino acid sequence that specifies the antibody, and which DNA sequence or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology available and well known in the art.
[0064] (B. Cells expressing ADR) Allogeneic cells used for adoptive transfer tend to be of limited efficacy due to immune responses by the recipient individual. In some cases, cells can be modified to remove endogenous TCRs (e.g., using CRISPR) to prevent, for example, graft-versus-host disease, but alternatively, virus-specific T cells (intact or CAR / TCR modified) can be utilized to retain antiviral activity, which is useful in certain pathological conditions. Such VSTs have very limited graft-versus-host activity because their TCRs are more restricted to viral antigens, but are still susceptible to adverse reactions by the recipient.
[0065] Cells that have been modified to express synthetic ADR molecules and thus are improved for allogeneic use are encompassed by the present disclosure. Thus, the present disclosure includes cells that carry ADRs both as polynucleotides and as ADR polypeptides expressed on the surface of the cells. In certain cases, ADR-expressing cells are produced for the purpose of being maintained in a repository for off-the-shelf use. The cells may be housed in the repository already configured to express ADRs, or may be housed in a bank and configured to express ADRs after recovery from the repository. While certain cells, e.g., bacterial cells, may be utilized to generate ADR molecules, other cells, e.g., eukaryotic cells, that carry ADRs can be used in the methods of the present disclosure, including targeting of activated T cells. As shown herein, ADR-expressing immune cells selectively eliminate activated T cells, and ADR-expressing immune cells are protected from cytolysis by alloreactive T cells.
[0066] The cells expressing ADR molecules can be of any type, but in specific embodiments, they are immune cells, such as immune effector cells, such as T cells, NK cells, NKT cells, or cell lines derived from such lineages, that are modified to express ADR and therefore not found in nature, or cell lines engineered to have cytotoxic activity. Populations of non-natural ADR-expressing cells are contemplated, including populations in which at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% of the population are ADR-expressing cells. The cells can be generated by standard methods, for example, standard transfection or transduction methods of synthetic ADR polynucleotides.
[0067] In some cases, the ADR molecule modified to express the ADR molecule may already be engineered to have another engineered non-natural molecule other than the ADR, or it may be later engineered to have another engineered non-natural molecule other than the ADR. For example, cells expressing a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR) may do so to protect them from host rejection and therefore increase their therapeutic potency. Cells expressing one or more CARs and / or one or more TCRs may be engineered to express one or more ADRs, and cells expressing one or more ADRs may be engineered to express one or more CARs and / or one or more TCRs. Thus, in some cases, the ADR is expressed on a different vector than the CAR and / or TCR, and in other cases, the ADR molecule is expressed on the same vector as the CAR and / or TCR. In cases where the ADR is expressed on the same vector as the CAR (as an example), the ADR expression and the CAR expression may be directed by the same or different regulatory elements. In each case, the ADR and CAR can be expressed as a single polypeptide, with a cleavable element, such as 2A, between them.
[0068] In cases where the ADR-expressing cell also expresses a CAR or a TCR, the CAR or TCR can target any particular antigen. In cases where a CAR is used, the CAR can be a first generation, second generation, third generation, etc. The CAR can be bispecific in certain cases.
[0069] In some cases, cells expressing ADR molecules are engineered, e.g., engineered to lack expression of one or more endogenous molecules. In a specific case, cells are engineered to lack expression of one or more endogenous genes that would otherwise promote fratricide of the cells. In a specific case, cells expressing ADR molecules are engineered to lack expression of, e.g., 4-1BB or OX40. By way of example only, cell engineering may be performed by CRISPR / Cas9.
[0070] [II. Methods using self / alloimmune defense receptors] The embodiments of the present disclosure include a method of providing an effective amount of ADR-expressing cells to an individual for any purpose. The method includes providing selective targeting of activated T cells in an individual for any purpose. The activated T cells are targeted by exposing the activated T cells to an effective amount of ADR-expressing immune cells, e.g., ADR-expressing T cells. Such exposure can have one or more resulting applications, for example.
[0071] In some embodiments, ADRs are used to selectively target activated immune cells other than activated T cells, such as activated B cells (which may be useful for controlling unwanted B cells, such as in lupus, rheumatoid arthritis, etc.), as well as to target innate immune activation (e.g., macrophage activation syndrome, etc.) In another embodiment, ADRs are utilized to specifically target malignant cells expressing the respective target, such as 4-1BB or OX40 or CD40L.
[0072] The regimen for providing an effective amount of ADR-expressing cells to an individual can be known or determined by the person or people delivering the cells for treatment or prevention, or regardless of the method of use. For example, for prevention, the cells can be delivered prior to detection of one or more symptoms, or after detection of one or more symptoms, but before further symptoms occur and / or worsen. For treatment, an individual can be provided with an effective amount of cells after the occurrence of one, two or more symptoms, and in some cases after clinical diagnosis.
[0073] In specific embodiments of the method, the individual may receive a single administration of a therapeutically effective amount of cells, or may receive multiple deliveries of a therapeutically effective amount of cells, such as multiple deliveries at intervals of 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, or 4 weeks, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, or 1, 2, 3, 4, 5 years or more, or any range therebetween. The time between administrations may vary even within a single regimen.
[0074] Administration of the ADR-expressing cells can be by any suitable route to an individual, including local or systemic administration. In specific embodiments, the ADR-expressing cells are delivered, for example, intravenously, orally, rectally, topically, intramuscularly, by injection, enterally, nasally, by inhalation, sublingually, buccally, transdermally, or subcutaneously. The cells may or may not be delivered as a bolus. In the case of multiple administrations, the cells may or may not be provided to the individual by different delivery routes. When the cells are delivered to an individual, they may be delivered in a pharma- ceutically acceptable carrier or excipient. Specific examples of doses of the ADR-expressing cells include 10 4 cells / m 2 , 10 5 cells / m 2 , 10 6 cells / m 2 , 10 7 cells / m 2 , 10 8 cells / m 2 , 109 cells / m 2 , 10 10 cells / m 2 , 10 11 cells / m 2 , or 10 12 cells / m 2 and ranges therebetween.
[0075] A. Embodiments for use off-the-shelf The present disclosure encompasses cells for adoptive transfer that are available off the shelf, e.g., can be obtained from a repository for use in an individual different from the individual from which the cells were originally obtained. The cells may already express an ADR before being deposited in the repository, or may be modified to express an ADR later. The cells may be any type of immune effector cell for adoptive transfer. The cells before being deposited in the repository or after being obtained from the repository may be modified to express, for example, a tumor-specific receptor (e.g., a CAR or TCR).
[0076] As shown elsewhere herein, cells expressing ADRs selectively target activated T cells and NK cells while sparing resting T cells. ADRs protect allogeneic T cells from immune rejection mediated by T cells and / or NK cells in vitro, and protect T cells from immune rejection in vivo. In so doing, ADRs do not interfere with the function of engineered anti-tumor receptors (CARs, for example), as T cells co-expressing ADRs and CARs can efficiently eliminate both tumors and activated T cells in vitro. The present disclosure further uses "off-the-shelf" T cells co-expressing CARs and ADRs to provide anti-cancer activity in vivo in mouse models while remaining resistant to immune rejection from allogeneic T cells present in the same mouse. As an example, FIG. 14 shows that 4-1BB ADRs are effective against 4-1BB+ tumor cells, and ADRs can be used as a therapeutic modality against 4-1BB-expressing malignancies.
[0077] In certain embodiments, "off-the-shelf" therapeutic cells express ADRs to resist immune rejection and either retain endogenous TCR specificity (e.g., specificity for a viral or tumor antigen) or have the endogenous TCR replaced with an engineered anti-tumor receptor, e.g., one or more CARs and / or one or more recombinant TCRs.
[0078] In a specific embodiment, pre-made cells are housed in a repository and can be modified for a specific purpose before or after deposit in the repository. For example, ADR-expressing T cells can be housed in a repository and ready to use, for example, to prevent graft rejection after tissue or organ transplantation. ADR-expressing T cells can be housed in a repository and selected or engineered with native or transgenic TCRs, for example, to combat viral infections or cancer. ADR-expressing T cells can be housed in a repository and transduced with a CAR directed against cancer or pathogenic infection. ADR-expressing cells can be housed in a repository and transduced with one or more CARs and / or one or more TCRs directed against specific cancer-associated antigens or neo-antigens expressed by a specific tumor of the patient.
[0079] In some cases, banked allogeneic cells are utilized to prevent rejection of solid organ transplants by destroying the host's rejecting immune cells, particularly when the ADR-expressing cells are not themselves alloreactive.
[0080] While the cells contained in the repository can be allogeneic with respect to the recipient individual, in alternative embodiments, the cells contained in the repository are autologous to the recipient individual. For example, an individual with cancer can have ADR-expressing T cells deposited in the repository for later use, such as when the cancer goes out of remission. In other cases, autologous ADR-expressing cells are contained in the repository to treat an autoimmune disorder.
[0081] B. Use in Autoimmune Disorders Unwanted activation of endogenous autoreactive T cells in an individual can lead to devastating autoimmune diseases for that individual, such as diabetes mellitus, autoimmune colitis, and multiple sclerosis. In certain embodiments, one or more autoimmune disorders are prevented or treated by using ADR-expressing immune cells in an individual, which affect the autoimmune disorder (or its potential occurrence) by inhibiting endogenous autoreactive T cells in the individual. In specific embodiments, the use of such ADR-expressing cells preserves resting non-pathogenic naive and memory T cells in the individual. Thus, certain methods of the present disclosure utilize specific cells modified to express ADRs, which are provided to an individual in sufficient amounts to target activated T cells, including pathogenic T cells, thereby initiating the destruction of activated T cells.
[0082] In vivo activation of T cells with unwanted specificities can lead to pathogenicity, and in certain embodiments, cells expressing one or more ADRs target activated T cells, in some cases the ADR-expressing cells target pathogenic cells, which are a subset of activated T cells.
[0083] In certain cases, ADR-expressing T cells can be used to prevent or reverse life-threatening and debilitating conditions driven by activated T cells (e.g., organ rejection, graft-versus-host disease, type I diabetes, multiple sclerosis, autoimmune colitis, lupus, rheumatoid arthritis, etc.) using adoptive T cell transfer of ADR-expressing T cells.
[0084] In some cases, the ADR-expressing T cells also comprise one or more compositions other than an ADR that facilitate the treatment or prevention of one or more autoimmune disorders.
[0085] In some cases, the individual provided with the ADR-expressing T cells is given one or more additional therapies to prevent or treat one or more autoimmune disorders. The individual may or may not be given one or more immunosuppressants, such as glucocorticoids, cytostatics, drugs that act on antibodies and / or immunophilins, etc. Additionally or alternatively, the individual may be given one or more suitable vaccines.
[0086] In some cases, an individual is at risk of an autoimmune disorder, and an effective amount of ADR-expressing cells is provided to prevent the onset of an autoimmune disorder, or to delay the onset and / or alleviate one or more symptoms, such as severity and / or duration. An individual at risk of an autoimmune disorder may be, for example, a person with a personal or family history, a woman of a particular ethnicity, etc. An individual may have an autoimmune disorder, and in some cases, desire to prevent or reduce the severity and / or duration or delay the onset of another autoimmune disorder.
[0087] Examples of autoimmune disorders that may be prevented or treated with ADR-expressing cells include at least the following: achalasia; Addison's disease; adult Still's disease; agammaglobulinemia; alopecia areata; amyloidosis; ankylosing spondylitis; anti-GBM / anti-TBM nephritis; antiphospholipid syndrome; autoimmune angioedema; autoimmune autonomic neuropathy; autoimmune encephalomyelitis; autoimmune hepatitis; autoimmune inner ear disease (AIED); autoimmune myocarditis; autoimmune oophoritis; autoimmune orchitis; autoimmune pancreatitis; autoimmune retinopathy; autoimmune urticaria; axonal and neuronal neuropathy (AMAN); Barro's disease; Behcet's disease; benign mucous membrane pemphigoid; bullous pemphigoid; Castleman's disease; disease:CD);celiac disease;Chagas disease;chronic inflammatory demyelinating polyneuropathy (CIDP);chronic recurrent multifocal osteomyelitis (CRMO);Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA);cicatricial pemphigoid;Cogan syndrome;cold agglutinin disease;congenital heart block;Coxsackie myocarditis;CREST syndrome;Crohn's disease;dermatitis herpetiformis;dermatomyositis;Devic's disease (neuromyelitis optica);discoid lupus;Dressler syndrome;endometriosis;eosinophilic esophagitis esophagitis (EoE);eosinophilic fasciitis;erythema nodosum;essential mixed cryoglobulinemia;Evans syndrome;fibromyalgia;fibrosing alveolitis;giant cell arteritis (temporal arteritis);giant cell myocarditis;glomerulonephritis;Goodpasture syndrome;granulomatosis with polyangiitis;Graves disease;Guillain-Barré syndrome;Hashimoto's thyroiditis;hemolytic anemia;Henoch-Schonlein purpura (HSP);herpes gestationis or pemphigoid gestationis (PG);Hidradenitis Suppurativa (HS) (acne contralateralis);Hypogammaglobulinemia;IgA nephropathy;IgG4-related sclerosing disease;Immune thrombocytopenic purpura (ITP);Inclusion body myositis (IBM);Interstitial cystitis (IC);Juvenile arthritis;Juvenile diabetes mellitus (type 1 diabetes);Juvenile myositis (JM);Kawasaki disease;Lambert-Eaton syndrome;Leukocytoclastic vasculitis;Lichen planus;Lichen sclerosus;Lyngoconjunctivitis;Linear IgA disease (LAD);Lupus;Chronic Lyme disease;Meniere's disease;Microscopic polyangiitis (MPA);Mixed connective tissue disease disease (MCTD);Mohren's ulcer;Much-Habermann disease;Multifocal Motor Neuropathy (MMN) or MMNCB;Multiple sclerosis;Myasthenia gravis;Myositis;Narcolepsy;Neonatal lupus;Neuromyelitis optica;Neutropenia;Ocular cicatricial pemphigoid;Optic neuritis;Palindromic rheumatism (PR);PANDAS;Paraneoplastic cerebellar degeneration (PCD);Paroxysmal nocturnal hemoglobinuria (PNH);Parry-Romberg syndrome;Primary uveitis (peripheral uveitis);Parsonnage-Turner syndrome;Pemphigus;Peripheral neuropathy;Perivenous encephalomyelitis;Pernicious anemia anemia (PA);POEMS syndrome;polyarteritis nodosa;polyglandular syndrome types I, II, and III;polymyalgia rheumatica;polymyositis;post-myocardial infarction syndrome;post-pericardiotomy syndrome;primary biliary cirrhosis;primary sclerosing cholangitis;progesterone dermatitis;psoriasis;psoriatic arthritis;pure red cell aplasia (PRCA);pyoderma gangrenosum;Raynaud's phenomenon;reactive arthritis;Reflex sympathetic dystrophy;Relapsing polychondritis;Restless legs syndrome (RLS);Retroperitoneal fibrosis;Rheumatic fever;Rheumatoid arthritis;Sarcoidosis;Schmidt syndrome;Scleritis;Scleroderma;Sjogren's syndrome;Sperm&testicular autoimmunity;Stiff person syndrome (SPS);Subacute bacterial endocarditis (SBE);Suzac syndrome;Sympathetic ophthalmia (SO);Takayasu's arteritis;Temporal arteritis / giant cell arteritis;Thrombocytopenic purpura (TTP);Tolosa-Hunt syndrome (THS);Transverse myelitis;Type 1 diabetes;Ulcerative colitis (UC);Undifferentiated connective tissue disease UCTD); uveitis; vasculitis; vitiligo; Vogt-Koyanagi-Harada disease; and Wegener's granulomatosis (or Granulomatosis with Polyangiitis (GPA)).
[0088] (C. Use to eliminate NK cells) ADR-expressing immune cells may be utilized to eliminate NK cells in instances where it is desirable to eliminate NK cells. As demonstrated herein, the presence of ADRs on certain immune cells is related to HLA low Thus, for example, adoptive transfer of allogeneic cells to a particular individual may be utilized. lowIn situations where it is desirable to maintain cells or HLA-mismatched cells, the use of ADR-expressing cells avoids the activation of NK cells and the rejection of HLA-mismatched cells.Specifically, as shown herein, co-culture of T cells expressing ADR leads to the elimination of NK cells, thus counteracting the NK cell-mediated host rejection of ADR-expressing allogeneic T cells.
[0089] D. Use to Promote Engraftment of Allogeneic Cell / Tissue / Organ Transplants In a specific embodiment, avoiding activation of alloreactive T cells can avoid rejection of allogeneic cells, tissues or organs in an individual receiving transplantation, which is mainly mediated by a population of alloreactive T cells from the recipient. Activation of alloreactive T cells in the recipient would lead to, for example, engraftment failure if measures are not taken to avoid such rejection. Therefore, in certain embodiments, the method of transplanting cells, tissues or organs into an individual utilizes delivery of an effective amount of ADR-expressing cells before, during and / or after transplantation of each of the cells, tissues or organs. In some cases, the ADR-expressing cells themselves are not part of each cell, tissue or organ that is the subject of transplantation, while in other cases, the ADR-expressing cells are part of each cell, tissue or organ.
[0090] The tissue for transplantation may be of any type, such as at least skin, cornea, bone, tendon, heart valve, vein, or artery. The organ for transplantation may be of any type, such as heart, kidney, liver, lung, pancreas, intestine, and thymus.
[0091] In certain embodiments, ADR-expressing cells enhance the use of allogeneic cells in an individual as a two-pronged approach: (1) inhibiting endogenous alloreactive T cells in the individual, and (2) suppressing NK cell-mediated rejection in the individual. Thus, ADR molecules can enhance the survival and activity in an individual of allogeneic therapeutic cells, such as T cells, NK cells, NK-T cells, mucosal associated invariant T cells (MAIT) and other cytotoxic cells, of any type of third-party derived therapeutic cell, including those expressing engineered constructs such as chimeric antigen receptors (CARs), transgenic TCRs, etc.
[0092] E. Use in preventing or treating graft-versus-host disease (GvHD) during allogeneic cell / tissue / organ transplantation In another specific embodiment, avoiding activation of alloreactive T cells may avoid life-threatening alloimmune responses in individuals receiving transplants of allogeneic cells, tissues, or organs. Such transplants contain donor alloreactive T cells that, unless measures are taken to avoid their activation, would induce, for example, the development of graft-versus-host disease (GvHD). Thus, in certain embodiments, the method of transplanting cells, tissues, or organs into an individual utilizes the delivery of an effective amount of ADR-expressing cells before, during, and / or after transplantation of each of the cells, tissues, or organs. In some cases, the ADR-expressing cells themselves are not part of each cell, tissue, or organ that is the subject of transplantation, while in other cases, the ADR-expressing cells are part of each cell, tissue, or organ.
[0093] The tissue for transplantation may be of any type, such as at least skin, cornea, bone, tendon, heart valve, vein, or artery. The organ for transplantation may be of any type, such as heart, kidney, liver, lung, pancreas, intestine, and thymus.
[0094] III. Production of ADR-Expressing Cells Cells expressing an ADR molecule may be produced in a variety of ways, any of which may be routine in the art. The production method may include obtaining a cell that is modified to express the ADR molecule. The production method may also include generating the ADR molecule.
[0095] (Source of AT cells) Prior to the expansion and genetic modification of the ADR-expressing T cells of the present disclosure, a source of T cells may be obtained from a subject. Such a obtaining step may or may not be part of the present method. In some cases, obtaining the T cells to be modified and their manipulation may be performed by a different party than the party providing the ADR-expressing T cells to the individual. T cells may be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Certain embodiments of the present disclosure may use many T cell lines available in the art. In certain embodiments, T cells may be obtained from a unit of blood collected from a subject using many techniques known in the art, such as Ficoll™ separation. In one embodiment, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including, for example, T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, cells collected by apheresis may be washed to remove the plasma fraction and place the cells in an appropriate buffer or medium for subsequent processing steps. In one embodiment, the cells are washed with phosphate buffered saline (PBS). In alternative embodiments, the wash solution lacks calcium, may lack magnesium, or may lack many, if not all, divalent cations. As will be readily understood by one of ordinary skill in the art, the washing step may be accomplished by methods known to those of skill in the art, for example, by using a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processing machine, Baxter CytoMate, or Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells may be washed with, for example, phosphate buffered saline (PBS), or phosphate buffered saline (PBS). In alternative embodiments, the wash solution lacks calcium, may lack magnesium, or may lack many, if not all, divalent cations. As will be readily understood by those of ordinary skill in the art, the washing step may be accomplished by methods known to those of ordinary skill in the art, for example, by using a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processing machine, Baxter CytoMate, or Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells may be washed with, for example, Ca2+ Free Mg 2+ The cells may be resuspended in a variety of biocompatible buffers, such as free PBS, PlasmaLyte A, or other saline solutions with or without buffers. Alternatively, undesirable components of the apheresis sample may be removed and the cells resuspended directly in culture medium.
[0096] In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing red blood cells and depleting monocytes, for example by centrifugation on a PERCOLL™ gradient or by counterflow centrifugal elutriation. Specific subpopulations of T cells, such as CD3 + , CD28 + , CD4 + , CD8 + , CD45RA + , and CD45RO + T cells can be further isolated by positive or negative selection methods.
[0097] Enrichment of a T cell population by negative selection can be achieved using a combination of antibodies directed against surface markers unique to the cells being negatively selected. One method is cell sorting and / or cell selection by negative magnetic immunoadhesion or negative flow cytometry using a cocktail of monoclonal antibodies directed against cell surface markers present on the cells being negatively selected. For example, enrichment of a T cell population by negative selection can be achieved by using a combination of antibodies directed against surface markers unique to the cells being negatively selected. + To enrich for cells, the cocktail of monoclonal antibodies typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, typically CD4 + , CD25 + , CD62L hi , G.I.T.R. + , and FoxP3 +It may be desirable to enrich or positively select for regulatory T cells expressing T-cell IL-1, T-cell IL-1, T-cell IL-2, T-cell IL-1, T-cell IL-2, T-cell IL-3, T-cell IL-4, T-cell IL-5, T-cell IL-6, T-cell IL-7, T-cell IL-8, T-cell IL-9, T-cell IL-10, T-cell IL-11, T-cell IL-12, T-cell IL-13, T-cell IL-14, T-cell IL-15, T-cell IL-16, T-cell IL-17, T-cell IL-18, T-cell IL-19, T-cell IL-21, T-cell IL-22, T-cell IL-23, T-cell IL-24, T-cell IL-25, T-cell IL-25, T-cell IL-25, T-cell IL-3, T-cell IL-4, T-cell IL-5, T-cell IL-19, T-cell IL-19, T-cell IL-19, T-cell IL-25, T-cell IL-14, T-cell IL-15, T-cell IL-19, T-cell IL-19, T-cell IL-24, T-cell IL-19, T-cell IL-19, T-cell IL-25, T-cell IL-14, T-cell IL-15, T-cell IL-19, T-cell IL-19, T-cell IL-25, T-cell IL-19, T-cell IL-19, T-cell IL-23, T-cell IL-19, T-cell IL-19, T-cell IL-24, T-cell IL-19, T-cell IL-
[0098] For the isolation of a desired cell population by positive or negative selection, the concentration and surface of the cells (e.g., particles such as beads) can vary. In certain embodiments, it may be desirable to significantly reduce the volume in which the beads and cells are mixed together (i.e., increase the concentration of cells) to ensure maximum contact between the cells and the beads. For example, in one embodiment, a concentration of 2 billion cells / ml is used. In one embodiment, a concentration of 1 billion cells / ml is used. In a further embodiment, more than 100 million cells / ml is used. In a further embodiment, a cell concentration of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells / ml is used. In yet another embodiment, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells / ml is used. In further embodiments, a concentration of 125 or 150 million cells / ml can be used. The use of higher concentrations can result in increased cell yield, cell activation and cell proliferation. In another embodiment, it may be desirable to use lower cell concentrations. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between particles and cells are minimized.
[0099] T cells for stimulation can also be frozen after a washing step. Without wishing to be bound by theory, the freezing and subsequent thawing steps provide a more uniform product by removing granulocytes, and to some extent monocytes, in the cell population. After a washing step to remove plasma and platelets, the cells can be suspended in a freezing solution. Many freezing solutions and freezing parameters are known in the art. In certain embodiments, the cryopreserved cells are thawed and washed as described herein and allowed to rest at room temperature for 1 hour before activation using the methods of the present invention.
[0100] It is also contemplated in the context of the present disclosure to collect blood samples or apheresis products from a subject at a time prior to the time that the expanded cells described herein may be needed. In this way, a source of cells to be expanded can be collected at any time required, and the desired cells, e.g., T cells, can be isolated and frozen for later use in T cell therapy for many diseases or conditions for which T cell therapy would be beneficial, such as those described herein. In one embodiment, blood samples or apheresis are taken from generally healthy subjects. In certain embodiments, blood samples or apheresis are taken from generally healthy subjects who are at risk of developing disease but have not yet developed disease, and cells of interest are isolated and frozen for later use. In certain embodiments, T cells can be expanded, frozen, and used later. In certain embodiments, samples are collected from patients shortly after diagnosis of a particular disease described herein, but prior to any treatment. In a further embodiment, the cells are isolated from a blood sample or apheresis from a subject prior to a number of relevant treatment modalities, including, but not limited to, treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolic acid and FK506, antibodies, or other immune ablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and radiation. These drugs inhibit calcineurin, a calcium-dependent phosphatase (cyclosporine and FK506), or inhibit p70S6 kinase, which is important for growth factor-induced signaling (rapamycin) (Liu et al, Cell 66:807-815, 1991; Henderson et al, Immun. 73:316-321, 1991; Bierer et al, Curr.Opin.Immun. 5:763-773, 1993).In a further embodiment, the cells are isolated for a patient and frozen for later use in conjunction with (e.g., prior to, concurrently with, or subsequent to) bone marrow or stem cell transplantation, or T cell ablative therapy with chemotherapeutic agents such as fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cells can be pre-isolated and frozen for later use in treatment following B cell ablative therapy, such as agents reactive with CD20, e.g., Rituxan.
[0101] (Activation and proliferation of BT cells) Either before or after genetic modification of the T cells to express an ADR, the T cells may generally be modified as described in, e.g., U.S. Patent Nos. 6,352,694, 6,534,055, 6,905,680, 6,692,964, 5,858,358, 6,887,466, 6,905,681, 7,144,575, 7,144,576, 7,144,577, 7,144,578, 7,144,579 ... The T cells of the present disclosure can be activated and expanded using the methods described in US Patent Nos. 5,883,223, 6,905,874, 6,797,514, 6,867,041, and US Patent Publication No. 20060121005. In general, the T cells of the present disclosure are expanded by contact with a surface that is affixed with an agent that stimulates CD3 / TCR complex-associated signals and a ligand that stimulates costimulatory molecules on the T cell surface. Such processes are known in the art. In another example, T cells can be modified to express ADRs without prior activation.
[0102] (C. Generation of ADR molecules) Referring now to the polynucleotides encoding ADRs in general, the nucleic acid sequences encoding ADR molecules can be obtained using recombinant methods known in the art, for example by screening libraries from cells expressing the gene, or by removing the gene from a vector known to contain it, or by directly isolating it from cells and tissues containing it, using standard techniques. Alternatively, the ADR polynucleotide of interest can be produced synthetically, rather than cloned.
[0103] In brief summary, expression of synthetic polynucleotide encoding ADR is typically achieved by operably linking the nucleic acid encoding ADR polypeptide or a portion thereof to a promoter and incorporating the construct into an expression vector.The vector may be suitable for replication and integration in eukaryotes.Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters that help regulate the expression of desired nucleic acid sequences.
[0104] ADR polynucleotide can be cloned into several types of vectors.For example, nucleic acid can be cloned into vectors such as, but not limited to, plasmid, phagemid, phage derivative, animal virus and cosmid.Particularly interesting vectors include expression vectors, replication vectors, probe generation vectors and sequencing vectors.
[0105] Furthermore, expression vectors can be provided to cells in the form of viral vectors.Viral vector technology is well known in the art and described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. Viruses useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, suitable vectors contain a replication origin functional in at least one organism, a promoter sequence, a convenient restriction endonuclease site, and one or more selectable markers (e.g., WO01 / 96584; WO01 / 29058; and U.S. Patent No. 6,326,193).
[0106] Several virus-based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged into a retroviral particle using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of a subject either in vivo or ex vivo. Several retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Several adenoviral vectors are known in the art. In one embodiment, a lentiviral vector is used.
[0107] Additional promoter elements, such as enhancers, regulate the frequency of transcription initiation. Typically, these are located in the region 30-110 bp upstream of the start site, but some promoters have recently been shown to contain functional elements downstream of the start site. The spacing between promoter elements is often flexible, so that elements can be inverted or moved relative to one another while still maintaining promoter function. In the thymidine kinase (tk) promoter, increasing the spacing between promoter elements by up to 50 bp does not begin to reduce activity. Depending on the promoter, individual elements appear to be able to function either in concert or independently to activate transcription.
[0108] One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high level expression of any polynucleotide sequence operably linked thereto. Another example of a suitable promoter is the Elongation Growth Factor-1 alpha (EF-1 alpha). However, other constitutive promoter sequences may also be used, such as, but not limited to, the Simian Virus 40 (SV40) early promoter, the mouse mammary tumor virus (MMTV), the human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, the MoMuLV promoter, the avian leukosis virus promoter, the Epstein-Barr virus immediate early promoter, the Rous sarcoma virus promoter, and human gene promoters, such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. Furthermore, the present invention is not limited to the use of constitutive promoters. Inducible promoters are contemplated as part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on expression of a polynucleotide sequence to which it is operably linked when such expression is desired, and turn off expression when such expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionine promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0109] To evaluate the expression of ADR polypeptide or its part, the expression vector introduced into the cell can also contain a selectable marker gene or a reporter gene or both to facilitate the identification and selection of expressing cells from a population of cells to be transfected or infected with a viral vector.In another embodiment, the selectable marker can be carried on a separate DNA fragment and used in the co-transfection procedure.The selectable marker and the reporter gene can be flanked by appropriate regulatory sequences to allow expression in the host cell.Useful selectable markers include antibiotic resistance genes, such as neo.
[0110] Reporter genes are used to identify potentially transfected cells and to evaluate the functionality of regulatory sequences. In general, reporter genes are genes that are not present or expressed in the recipient organism or tissue, and that code for a polypeptide whose expression can be manifested by some easily detectable property, such as enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA is introduced into the recipient cells. Suitable reporter genes can include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase or secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479:79-82). Suitable expression systems are well known and can be prepared using known techniques or obtained commercially. In general, the construct with the smallest 5' flanking region that shows the highest level of reporter gene expression is identified as the promoter. Such promoter regions can be linked to a reporter gene and used to evaluate agents for their ability to modulate promoter-driven transcription.
[0111] The method of introducing ADR polynucleotide into cell and expressing it there is known in the art.In the case of expression vector, vector can be easily introduced into host cell, such as mammalian cell, bacterial cell, yeast cell or insect cell, by any method in the art.For example, expression vector can be transferred into host cell by physical, chemical or biological means.
[0112] Physical methods for introducing ADR polynucleotide into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. For example, see Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). One method for introducing polynucleotide into host cells is calcium phosphate transfection.
[0113] Biological methods for introducing the ADR polynucleotide of interest into host cell include DNA vector and RNA vector.Virus vector, especially retrovirus vector, has become the most widely used method for inserting genes into mammalian cells, such as human cells.Other virus vectors can be derived from lentivirus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus, etc.See, for example, U.S. Patent No. 5,350,674 and U.S. Patent No. 5,585,362.
[0114] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, such as oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0115] In the case of utilizing a non-viral delivery system, an exemplary delivery vehicle is a liposome. The use of lipid formulations to introduce nucleic acids into host cells (in vitro, ex vivo or in vivo) is envisioned. In another embodiment, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of the liposome, interspersed within the lipid bilayer of the liposome, attached to the liposome by a linking molecule associated with both the liposome and the oligonucleotide, entrapped in the liposome, complexed with the liposome, dispersed in a solution containing lipid, mixed with lipid, combined with lipid, contained as a suspended substance in lipid, contained with micelles, complexed with micelles, or otherwise associated with lipid. The lipid, lipid / DNA or lipid / expression vector associated compositions are not limited to any particular structure in solution. For example, they may exist as micelles or in a bilayer structure with a "collapsed" structure. They may simply be dispersed in the solution, and may form aggregates that are not uniform in size or shape. Lipids are fatty substances, and may be natural or synthetic lipids. For example, lipids include lipid droplets that naturally occur in cytoplasm, and classes of compounds that contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes.
[0116] Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma (St. Louis, MO), dicetyl phosphate ("DCP") can be obtained from K&K Laboratories (Plainview, NY), cholesterol ("Choi") can be obtained from Calbiochem-Behring, and dimyristyl phosphatidylglycerol ("DMPG") and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Stock solutions of lipids in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the only solvent because it evaporates more easily than methanol. "Liposome" is a generic term that encompasses a variety of single and multilamellar lipid vehicles formed by the formation of closed lipid bilayers or lipid aggregates. Liposomes can be characterized as having a vesicular structure with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before forming a closed structure, trapping water and dissolved solutes between the lipid bilayers (Ghosh et al., 1991 Glycobiology 5:505-10). However, compositions with dissolved structures that differ from the normal vesicular structure are also included. For example, lipids may be in micellar structures or simply exist as nonuniform aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also contemplated.
[0117] In some examples, ADR molecules can be integrated into endogenous nucleic acids of cells. If it is desired that the construct is integrated into a specific locus, a target site for homologous recombination can be provided. For example, materials and methods known in the art for homologous recombination can be used to knock out an endogenous gene and replace it (at the same locus or elsewhere) with the gene encoded by the construct. Either OMEGA vector or O-vector can be used for homologous recombination. CRISPR / Cas9, zinc finger nuclease, TALE nuclease, meganuclease, and other site-specific nucleases can be used to target and cut specific sites in the genome to promote homologous recombination.
[0118] Exemplary T cells that have been engineered to contain an ADR expression construct may be grown in culture under selective conditions, and cells selected as carrying the construct may then be expanded and further analyzed, such as using polymerase chain reaction to determine the presence of the construct in the host cells. Once engineered host cells have been identified, they may then be used as planned, for example, grown in culture and introduced into a host organism.
[0119] Depending on the nature of the cells, the cells may be introduced into a host organism, e.g., a mammal, in a wide variety of ways. In a specific embodiment, the cells may be introduced into the tumor site, while in alternative embodiments, the cells are modified so that they home to the cancer or to the infected tissue. The number of cells used will depend on several circumstances, the purpose of the introduction, the lifespan of the cells, the protocol used, e.g., the number of administrations, the doubling ability of the cells, the stability of the recombinant construct, etc. The cells may be applied as a dispersion, and are generally injected at or near the site of interest. The cells may be present in a physiologically acceptable medium.
[0120] It is not necessary in all cases that the introduction of DNA results in integration. In some circumstances, transient maintenance of the introduced DNA may be sufficient. This would allow for a short-term effect, turning on the cells a pre-determined time after they have been introduced into the host, for example after they have been able to home to a specific site. EXAMPLES
[0121] The following examples are presented to more particularly illustrate certain embodiments of the present disclosure, but should not be construed as in any way limiting the scope of the broad disclosure.
[0122] Example 1: Self / Alloimmune Defense Receptors for Selective Targeting of Pathogenic T Cells Disclosed herein is a novel approach to specifically target pathogenic T cells using autologous / allogeneic immune defense receptors (ADRs) expressed on normal T cells that find and eliminate only activated T cells, sparing the resting, non-pathogenic naive and memory T cells that make up the majority of circulating lymphocytes.
[0123] The concept of ADR-mediated targeting is based on the finding that within 24 hours of activation, T cells transiently upregulate the costimulatory genes 4-1BB, OX40 and / or CD40L on their cell surface. Expression of 4-1BB, OX40 and / or CD40L is maintained only while the T cell is actively cytotoxic and is gradually downregulated within 4-5 days once TCR signaling ceases. Notably, activated CD8 + T cells showed more intense 4-1BB expression, whereas CD4 +T cells preferentially expressed OX40 and / or CD40L. Besides activated T cells, ADR ligands may be expressed only on activated NK cells and some other non-essential recruitable cell subsets. This expression pattern of 4-1BB, OX40 and CD40L makes these genes attractive targets for targeting activated cells with high specificity while avoiding permanently damaging important immune and non-immune tissues.
[0124] To explore the feasibility of targeting these activated T cells, we designed an auto / alloimmune defense receptor (ADR) to be composed of a 4-1BB-specific ligand, an OX40-specific ligand or a CD40L-specific receptor directly connected via a spacer to the CD3ζ chain encoded in the gammaretroviral vector SFG. The spacer region was incorporated a) to allow the incorporation of type II proteins 4-1BBL and OX40L into the type I backbone of the ADR, and b) to facilitate detection of the ADR on the cell surface by FACS staining. Transduction of T cells with this construct efficiently forced ADR expression on the cell surface. These ADR T cells had potent and robust cytotoxicity against 4-1BB, OX40 and CD40L expressing cells, eliminating 90–99% of the target cells within 48 h. These results demonstrate the feasibility of generating functional 4-1BB, OX40 and CD40L-specific ADR T cells.
[0125] Since ADR signaling in T cells results in upregulation of 4-1BB, OX40 and CD40L, promoting sibling killing and preventing effector cell proliferation, we explored the effect of CRISPR / Cas9 genomic disruption of ADR target genes in effector T cells. We have previously shown that this CRISPR / Cas9 approach can prevent sibling killing of primary human T cells expressing a CD7-specific CAR. In this context, we were able to use CRISPR / Cas9 to knock out 4-1BB expression in approximately 70% of ADR T cells, which consistently downregulated 4-1BB without affecting cytotoxicity. + After 48 hours of co-culture with target cells, ADR T cell proliferation was increased by more than two-fold.
[0126] We next tested the ability of ADR T cells to selectively eliminate activated T cells. 4-1BB, OX40, and CD40L ADR T cells were co-cultured with fluorescently labeled resting or CD3 / CD28 activated T cells. + and CD8 + T cells were quantified by flow cytometry using cell counting beads. After 72 h of coculture with T cells expressing 4-1BB, OX40, or CD40L-specific ADR, there was no reactivity to resting autologous T cells (Figure 2B). In contrast, coculture of 4-1BB ADR T cells with CD3 / CD28-activated T cells resulted in the majority of CD8 + T cells and some CD4 + T cells were eliminated within 48 hours. Incubation with OX40 ADR T cells reduced the number of activated CD4 + Reciprocally high levels of T cell depletion and activated CD8 + This resulted in a modest depletion of T cells. CD40L ADR T cells were able to express activated CD4 + It produced a moderate cytotoxic effect on T cells, but not on CD8 + No effect was seen on activated CD4 T cells. + T cells and CD8 +OX40, CD40L and 4-1BB ADR on T cells The differential targeting profile of T cells correlates with the observed differences in the intensity and kinetics of OX40, CD40L and 4-1BB expression on each T cell subset. This property of ADR can be exploited to preferentially target either alloreactive or autoreactive T cells as required. ADR expression therefore allows T cells to specifically target activated (pathogenic) T cells while sparing resting cells, suggesting their clinical use.
[0127] We assessed whether virus-specific T cells (VSTs) expressing ADR could resist allorejection in an in vitro mixed lymphocyte reaction (MLR) assay. CMV-specific T cells were generated from HLA-A2-negative donors and transduced with control untransduced VSTs or ADR-transduced VSTs expressing alloreactive HLA-A2 + The control VSTs were mixed with PBMCs at a cell-to-cell ratio of 1:2. We then cultured the cells for 12 days. At the end of the co-culture, the control VSTs were HLA-A2 + VSTs expressing either the 4-1BB or OX40 ADR resisted rejection, whereas they were almost completely rejected by PBMCs. Taken together, these results demonstrate the feasibility and selectivity of targeting activated T cells using the newly developed ADR platform embodiment.
[0128] Example 2: Self / Alloimmune Defense Receptors for Selective Targeting of NK Cells ADR is HLA low It exhibits specific cytotoxic activity against NK cells, a key cell population that mediates the rapid rejection of immune or HLA-mismatched cells.
[0129] NK cells can recognize HLA-mismatched or low HLA-expressing cells as part of antitumor and antiviral immune surveillance. Thus, adoptive transfer of allogeneic cells into immunoreplete patients results in NK cell activation and rejection of HLA-mismatched cells. Here, we show that co-culture of T cells expressing 4-1BB and OX40-specific auto / alloimmune defense receptors (ADRs) would lead to NK cell elimination and thus counteract NK cell-mediated host rejection of ADR-equipped allogeneic T cells. Hence, ADRs not only inhibit alloreactive T cell responses but also suppress NK cell-mediated rejection, further supporting the application of ADRs to enhance the survival and activity of “off-the-shelf” therapeutic T cells.
[0130] [Example 3] ADR-expressing T cells eliminate target cells. ADRs can be expressed on the cell surface of immune cells to enhance cytotoxicity against their respective targets. Figure 1A illustrates an example of a schematic of ADR (labels such as GFP are optional). Expression of ADR on the surface of T cells was confirmed (Figure 1B). Cells proliferated comparably to controls (Figure 1C). (Figure 1D) ADR-expressing T cells were cytotoxic against target cells expressing the corresponding ADR ligand (Figure 1D). Figure 1E shows the proliferation of wild-type and 4-1BB KO T cells expressing 4-1BB ADR, and their cytotoxicity against 4-1BB+ targets. Proliferation and cytotoxicity could be further enhanced by knocking out the ADR ligand on T cells, and co-expression of ADR and its ligand on T cells is not required for ADR- T cell proliferation or function (Figure 1E).
[0131] Selective expression of ADR ligands on activated T cells allows their selective elimination by ADR T cells. Expression of ADR ligands on resting and activated T cells after TCR stimulation is determined in contrast (Figure 2A-C). There was no cytotoxicity of ADR T cells against resting CD4+ and CD8+ T cells, but there was elimination of activated CD4+ and CD8+ T cells by ADR T cells after 48 h of co-culture (Figure 2E).
[0132] As an example, expression of the 4-1BB ADR protects T cells from immune rejection in the MLR model. Representative dot plots showing that TCRKO T cells co-expressing the ADR are protected from rejection after co-culture with allogeneic PBMCs at an ADR T:PBMC ratio of 1:10 (Figure 3A). The absolute numbers of donor T cells and allogeneic T cells in PBMCs during co-culture (Figure 3B-C) are the same for virus-specific ADR T cells (Figure 3D-F).
[0133] Expression of ADR protects virus-specific allogeneic T cells from immune rejection in in vitro mixed lymphocyte reactions. Representative dot plots showing that ADR VSTs are protected from immune rejection by recipient allogeneic PBMCs (Figure 4A). Absolute numbers of recipient T cells and donor VSTs at various time points during the MLR are presented in Figures 4B and 4C.
[0134] In Figure 5, ADR VST retains antiviral function. ADR VST was co-cultured with monocytes pulsed with a viral pepmix. Monocyte counts showed that ADR VST eliminated virus-infected cells as well as unmodified VST.
[0135] Activated NK cells upregulate ADR ligands and can be selectively targeted by ADR T cells. Expression of 4-1BB is confirmed on resting and activated NK cells (Figure 6A-6B). The remaining number of resting versus activated NK cells after 24 h of co-culture with 4-1BB ADR T cells is determined (Figure 6C). In Figure 6D, MHC-depleted ADR T cells protect against immune rejection by allogeneic PBMCs by controlling NK cell proliferation. In Figure 6E, the absolute number of donor T cells and allogeneic NK cells during co-culture is determined. Upon 48 h of co-culture at a 1:1 E:T ratio, MHC-depleted ADR T cells resist immune rejection by NK cells (Figure 6F). ADR T cells control the proliferation of alloreactive NK cells during MLR with PBMCs (Figure 6G). The absolute number of NK cells is plotted in Figure 6H.
[0136] ADR expression protects allogeneic T cells from immune rejection in vivo. Figure 7A shows an example of a mouse model of immune rejection in which T cells from an HLA-A2+ donor were given to mice after sublethal irradiation, followed by allogeneic HLA-A2- T cells 4 days later. Control T cells from an HLA-A2- donor were rejected by day 18, whereas ADR-expressing cells were protected (Figure 7B). The absolute numbers of T cells from HLA-A2+ and HLA-A2- donors at various time points were determined (Figure 7C). In a modified in vivo model shown in Figure 7D, mice were given whole PBMCs (containing both T and NK cells) from donor 1 instead of allogeneic T cells. Representative flow plots in Figure 7E show that ADR T cells protected mice from immune rejection and from the rapid development of lethal GvHD.
[0137] Co-expression of CAR and ADR maintains the function of both receptors. Figure 8A shows an example of a schematic of immune cells co-expressing ADR and CAR. Co-expression of CAR and ADR on the cell surface was confirmed (Figure 8B). Figure 8C shows the cytotoxicity of CAR-ADR T cells against NALM-6 (CD19+ CAR target) as an example target. In Figure 8D, the cytotoxicity of CAR-ADR T cells against activated T cells (ADR target) was also determined. Figure 8E demonstrates the cytotoxic activity of CAR-ADR T cells against both targets when simultaneously co-cultured with both cell targets.
[0138] CAR-ADR T cells are protected from immune rejection and exert potent antitumor activity. An example of the mouse model and regimen is illustrated in Figure 9A. In one example regimen, mice received allogeneic T cells from donor 1 and b2mKO NALM6 24 hours apart, followed by a single dose of CAR-ADR T cells from donor 2. The dynamics of T cells from donor 2 in peripheral blood are shown in Figure 9B, and the dynamics of T cells from donor 1 in the experimental group are presented in Figure 9C. Figure 9D shows the leukemia burden in the mice, and the overall survival rate of the mice was also determined (Figure 9E).
[0139] Figures 13A-C. In a solid tumor model, CAR-ADR T cells are protected from immune rejection and exert potent antitumor activity. An example of a mouse model and treatment is outlined in Figure 10A. Here, mice received allogeneic T cells from donor 1 and the b2mKO neuroblastoma cell line CHLA255 24 hours apart, followed by a single dose of CAR-ADR T cells from donor 2. Donor 2 GD2 CAR T cells were rejected by D18, whereas CAR-ADR T cells resisted allogeneic rejection and persisted in peripheral blood (Figure 10B). Tumor burden in mice is shown in Figure 13C. Here, * shows heterologous GvHD-related deaths in the ATC+GD2 CAR T group.
[0140] TCR knockout CAR-ADR T cells are protected from immune rejection and exert potent antitumor activity. A schematic of the mouse model is presented in which mice received allogeneic T cells from donor 1 and b2mKO NALM6 24 hours apart, followed by a single dose of TCR-edited CAR-ADR T cells from donor 2 (Figure 11A). The dynamics of T cells from donor 2 in peripheral blood are presented (Figure 11B). The dynamics of donor 1 T cells in the experimental group are shown (Figure 11C). Leukemia burden in mice (Figure 11D) and overall mouse survival (Figure 11E) are presented.
[0141] ADR T cells protect mice from lethal xenogeneic GvHD. A schematic of the model is shown in Figure 12A, and the expansion of FFLuc-labeled ADR T cells in vivo is demonstrated (Figure 12B). The kinetics of weight gain and loss in mice was determined (Figure 12C). The overall survival rate of mice is illustrated (Figure 12D).
[0142] A second generation ADR ("ADR.28zeta") with a CD28 intracellular signaling domain was utilized (as an example). An example of the structure of ADR.28zeta is illustrated (Figure 13A). The in vitro cytotoxicity of ADR.28zeta against target expressing cells was determined (Figures 13B and 13C). ADR.28zeta protected mice from xenogeneic GvHD lines (Figure 13B). A schematic of the model (Figure 13D) is shown. The proliferation of FFLuc-labeled ADR.28zeta T cells in vivo was confirmed (Figure 13E). The kinetics of mouse weight gain and loss (Figure 13F) and overall mouse survival (Figure 13G) were determined.
[0143] Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made therein without departing from the spirit and scope of the design as defined by the appended claims. Furthermore, the scope of the present application is not limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described herein. As would be readily understood by a person of ordinary skill in the art, any existing or later developed process, machine, manufacture, composition of matter, means, method or step that performs substantially the same function or achieves substantially the same result as the corresponding embodiment described herein can be utilized in accordance with the present disclosure. It is therefore intended that the appended claims include within their scope such processes, machines, manufacture, compositions of matter, means, methods or steps.
Claims
1. An isolated polynucleotide comprising a sequence encoding a polypeptide, said polypeptide comprising (1) One or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or a functional fragment thereof, (2) Signaling domain that promotes T cell activation operatively linked to the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; The isolated polynucleotide, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
2. The polynucleotide of claim 1 , wherein the polypeptide comprises an OX40-specific ligand.
3. The polynucleotide of claim 1, wherein the polypeptide comprises a 4-1BB specific ligand.
4. The polynucleotide of claim 1 , wherein the polypeptide comprises a CD40L-specific ligand.
5. The polynucleotide of any one of claims 1 to 4, wherein the polypeptide further comprises one, two or more costimulatory domains.
6. The polynucleotide according to any one of claims 1 to 5, further comprising a sequence encoding a spacer between (1) and (2).
7. The polynucleotide of claim 6, wherein the spacer is 10 to 220 amino acids in length.
8. The polynucleotide of claim 7 , wherein the spacer has a sequence that facilitates surface detection by an antibody.
9. The polynucleotide of claim 8 , wherein the spacer is detectable with an anti-Fc Ab.
10. The polynucleotide of claim 9 , wherein the spacer comprises an IgG Fc portion.
11. The polynucleotide of any one of claims 1 to 10, wherein the polynucleotide further encodes a chimeric antigen receptor, a T cell receptor, or both.
12. 12. The polynucleotide of claim 11, wherein there is a 2A element or an IRES element on the polynucleotide encoding the polypeptide of claim 1 and on the polynucleotide encoding the chimeric antigen receptor, the T cell receptor, or both.
13. The polynucleotide of claim 12, wherein the chimeric antigen receptor comprises one, two or more costimulatory domains.
14. A vector comprising a polynucleotide described in any one of claims 1 to 13.
15. The vector of claim 14 , wherein the vector is a viral vector or a non-viral vector.
16. The vector of claim 15 , wherein the viral vector is a retroviral vector, a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.
17. A cell comprising a polynucleotide described in any one of claims 1 to 13.
18. The cell of claim 17 , wherein the cell is a eukaryotic cell or a bacterial cell.
19. The cell of claim 17 or claim 18, wherein the cell is an immune cell.
20. The cell of any one of claims 17 to 19, wherein the cell is engineered.
21. The cell of claim 19 , wherein the immune cell is a T cell.
22. 22. The cell of claim 21 , wherein the T cell comprises one or more chimeric antigen receptors.
23. 23. The cell of claim 22, wherein the chimeric antigen receptor comprises one, two or more costimulatory domains.
24. 22. The cell of claim 21 , wherein the T cell comprises one or more engineered T cell receptors (TCRs).
25. A polypeptide expressed by the polynucleotide of any one of claims 1 to 10.
26. (1) One or more of OX40 specific ligand, 4-1BB specific ligand, and CD40, (2) Signaling domain that promotes T cell activation operatively linked to the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; A polypeptide, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
27. The polypeptide of claim 26, wherein the signaling domain that promotes T cell activation is derived from a CD3 zeta subunit, DAP12, an Fc receptor, or a combination thereof.
28. 28. The polypeptide of claim 26 or claim 27, wherein the polypeptide further comprises one, two or more costimulatory domains.
29. A cell expressing a chimeric receptor comprising a polynucleotide according to any one of claims 1 to 13 or a polypeptide according to any one of claims 26 to 28.
30. 30. The cell of claim 29, which is an immune cell.
31. 31. The cell of claim 29 or claim 30, which is engineered.
32. The cell of claim 30 , wherein the immune cell is a T cell.
33. 33. The cell of claim 32, wherein the T cell is a CAR-transduced T cell.
34. 33. The cell of claim 32, wherein the T cell is a T cell receptor (TCR) transduced T cell.
35. 35. The cell of any one of claims 29 to 34, engineered to lack endogenous expression of one or more genes.
36. The cell of claim 35, which is engineered to lack endogenous expression of 4-1BB, OX40 and / or CD40L.
37. The cell of claim 35 or claim 36, engineered with CRISPR / Cas9, zinc finger nucleases, TALE nucleases, or meganucleases.
38. The cell of any one of claims 29 to 37, contained in a cell repository.
39. A method for preparing cells for cell therapy (excluding methods performed within the human body), comprising the step of transfecting immune effector cells with the polynucleotide of any one of claims 1 to 13.
40. 40. The method of claim 39, further comprising depositing the cells in a cell repository.
41. 41. The method of claim 39 or claim 40, further comprising modifying the cells to express one or more chimeric antigen receptors and / or one or more recombinant T cell receptors.
42. A composition for treating a medical condition comprising a therapeutically effective amount of a cell expressing a chimeric receptor according to any one of claims 29 to 38, said cell being allogeneic to said individual.
43. The composition of claim 42, wherein the cells are obtained from a cell repository.
44. 44. The composition of claim 42 or claim 43, wherein the cells express one or more chimeric antigen receptors and / or one or more recombinant T cell receptors.
45. 1. A composition for avoiding rejection of allogeneic cells, tissues or organs in an individual, comprising an effective amount of: an allogeneic immune cell expressing an engineered chimeric receptor comprising an extracellular domain comprising one or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or functional fragments thereof, and CD3 zeta; The cells are delivered to the individual to effect in the individual: (1) inhibition of endogenous alloreactive T cells in the individual; and / or (2) suppression of NK cell activation in the individual; the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; The composition, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
46. 46. The composition of claim 45, wherein the allogeneic cell is an allogeneic immune cell expressing a chimeric receptor.
47. The composition of claim 45 or claim 46, wherein the allogeneic cells express a chimeric antigen receptor or an engineered T cell receptor.
48. 46. The composition of claim 45, wherein the allogeneic immune cells are delivered to the individual before, during and / or after tissue and / or organ transplantation in the individual.
49. The composition of any one of claims 45 to 48, wherein the activated T cells are pathogenic T cells.
50. A composition for selectively targeting activated T cells in an individual, comprising an effective amount of immune cells expressing an engineered chimeric receptor, the chimeric receptor comprising (1) an extracellular domain comprising one or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or a functional fragment thereof; and (2) containing a signaling domain that promotes T cell activation; the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; The composition, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
51. The composition of claim 50, wherein the signaling domain that promotes T cell activation is derived from a CD3 zeta subunit, DAP12, an Fc receptor, or a combination thereof.
52. 52. The composition of claim 50 or claim 51, wherein the activated T cells are pathogenic T cells.
53. A composition for preventing or treating a medical condition associated with activated T cells in an individual, comprising an effective amount of immune cells expressing an engineered chimeric receptor that selectively targets the activated T cells, the chimeric receptor comprising (1) an extracellular domain comprising one or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or a functional fragment thereof; and (2) a signaling domain that promotes T cell activation; the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; The composition, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
54. The composition of claim 53, wherein the chimeric receptor further comprises one, two or more costimulatory domains.
55. 55. The composition of claim 53 or claim 54, wherein the medical condition is an autoimmune disorder.
56. 56. The composition of any one of claims 53-55, wherein the medical condition comprises transplant rejection, graft versus host disease, type I diabetes, multiple sclerosis, autoimmune colitis, or a combination thereof.
57. 1. A composition for avoiding NK cell-mediated host rejection of allogeneic T cells, tissue or organs in an individual, comprising an effective amount of: an immune cell expressing an engineered chimeric receptor comprising an extracellular domain comprising one or more of an OX40-specific ligand, a 4-1BB-specific ligand, a CD40L-specific ligand, or a functional fragment thereof, and a signaling domain that promotes T cell activation; the OX40-specific ligand is OX40L, an antibody targeting OX40, an OX40L-Fc fusion, or a combination thereof; the 4-1BB specific ligand is 4-1BBL, an antibody targeting 4-1BB, a 4-1BBL-Fc fusion, or a combination thereof; The composition, wherein the CD40L-specific ligand is CD40, an antibody that targets CD40L, a CD40-Fc fusion, or a combination thereof.
58. 58. The composition of claim 57, wherein the immune cell expressing the engineered chimeric receptor is an allogeneic T cell.
59. 59. The composition of claim 57 or claim 58, wherein the immune cells express a chimeric antigen receptor or an engineered T cell receptor.
60. The amount of immune cells expressing the engineered chimeric receptor provided to the individual is 1 ml 2 10 per 2 ~10 12 The composition according to any one of claims 57 to 59, in the range of
61. The composition of any one of claims 42 to 60, wherein cells expressing the chimeric receptor are provided to an individual systemically or locally.
62. The composition of any one of claims 42 to 61, which is a T cell.
63. 63. The composition of any one of claims 42 to 62, delivered once to the individual or delivered more than once.
Citation Information
Patent Citations
Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150203560A1
Engineered cells for adoptive cell therapy
WO2017011804A1
Cited By
Auto / allo-immune defense receptors for the selective targeting of activated pathogenic T cells and NK cells
US12617838B2
